This has led to the suggestion that in prion disease, where the central role of PrP in disease is incontrovertible (71), the lowering of CSF PrP—a target engagement biomarker only—could serve as a primary endpoint in trials of at-risk individuals (72). The gene discussed is PRNP; the disease is prion disease.